Dannielle Appelhans
2021
In 2021, Dannielle Appelhans earned a total compensation of $3.7M as Chief Operating Officer at Rubius Therapeutics.
Compensation breakdown
| Bonus | $130,000 |
|---|---|
| Non-Equity Incentive Plan | $76,870 |
| Option Awards | $2,185,155 |
| Salary | $177,404 |
| Stock Awards | $1,086,000 |
| Other | $38,706 |
| Total | $3,694,135 |
Appelhans received $2.2M in option awards, accounting for 59% of the total pay in 2021.
Appelhans also received $130K in bonus, $76.9K in non-equity incentive plan, $177.4K in salary, $1.1M in stock awards and $38.7K in other compensation.
Rankings
In 2021, Dannielle Appelhans' compensation ranked 3,615th out of 12,415 executives tracked by ExecPay. In other words, Appelhans earned more than 70.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,615 out of 12,415 | 71st |
Division Manufacturing | 1,473 out of 5,505 | 73rd |
Major group Chemicals And Allied Products | 600 out of 2,375 | 75th |
Industry group Drugs | 534 out of 2,096 | 75th |
Industry Biological Products, Except Diagnostic Substances | 140 out of 449 | 69th |
Source: SEC filing on March 30, 2022.
Appelhans' colleagues
We found four more compensation records of executives who worked with Dannielle Appelhans at Rubius Therapeutics in 2021.